Interpreting the results of the CATIE study.
Lieberman
Jeffrey A
JA
Hsiao
John K
JK
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000009:adverse effects; D006801:Humans; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy*; D013844:Thiazoles / Q000009:adverse effects; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D010546:Perphenazine; D018967:Risperidone